

**T.A. Dolan (Pharmacy) Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 31 March 2025**

**T.A. Dolan (Pharmacy) Limited**  
**CONTENTS**

|                                       | <b>Page</b> |
|---------------------------------------|-------------|
| Directors' Responsibilities Statement | 3           |
| Balance Sheet                         | 4 - 5       |
| Notes to the Financial Statements     | 6 - 11      |

# T.A. Dolan (Pharmacy) Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 March 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to F.D.C. Accountants-Tax Consultants Midlands Region Ltd., all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 March 2025."

### Signed on behalf of the board

Jean Dolan  
Director



23 December 2025

Robert Dolan  
Director



23 December 2025

**T.A. Dolan (Pharmacy) Limited****BALANCE SHEET**

as at 31 March 2025

|   | Notes | 2025<br>€        | 2024<br>€        |
|---|-------|------------------|------------------|
| <b>Fixed Assets</b>                                   |       |                  |                  |
| Tangible assets                                       | 7     | <u>1,621,560</u> | <u>1,699,559</u> |
| <b>Current Assets</b>                                 |       |                  |                  |
| Stocks  | 8     | 150,258          | 137,452          |
| Debtors   | 9     | 317,742          | 302,699          |
| Cash at bank and in hand                              |       | 16,336           | 20,345           |
|   |       | <u>484,336</u>   | <u>460,496</u>   |
| <b>Creditors: amounts falling due within one year</b> | 10    | <u>(562,577)</u> | <u>(477,360)</u> |
| <b>Net Current Liabilities</b>                        |       | <u>(78,241)</u>  | <u>(16,864)</u>  |
| <b>Total Assets less Current Liabilities</b>          |       | 1,543,319        | 1,682,695        |
| <b>Creditors:</b>                                     |       |                  |                  |
| amounts falling due after more than one year          | 11    | (254,792)        | (399,874)        |
| <b>Provisions for liabilities</b>                     | 13    | <u>(5,455)</u>   | <u>(4,907)</u>   |
| <b>Net Assets</b>                                     |       | <u>1,283,072</u> | <u>1,277,914</u> |
| <b>Equity</b>   |       |                  |                  |
| Called up share capital presented as equity           |       | 128              | 128              |
| Retained earnings                                     |       | 1,282,944        | 1,277,786        |
| <b>Equity attributable to owners of the company</b>   |       | <u>1,283,072</u> | <u>1,277,914</u> |

## T.A. Dolan (Pharmacy) Limited

### BALANCE SHEET

as at 31 March 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of T.A. Dolan (Pharmacy) Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 23 December 2025 and signed on its behalf by:

Jean Dolan  
Director



Robert Dolan  
Director



# T.A. Dolan (Pharmacy) Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

### 1. General Information

These financial statements constitute the individual financial statements of T.A. Dolan (Pharmacy) Limited for the financial year ended 31 March 2025.

T.A. Dolan (Pharmacy) Limited is a private company limited by shares (CRO number 76048) incorporated in Ireland. The registered office of the company is Main Street, Moate, Co. Westmeath which is also the principal place of business of the company. The principal activity of the company is the retail distribution of pharmaceutical products.

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

#### Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

|                                  |   |  |
|----------------------------------|---|--|
| Freehold land and buildings      | - | 2% Straight line                         |
| Long leasehold property          | - | Straight line over the life of the lease |
| Fixtures, fittings and equipment | - | 12.5% & 25% straight line                |

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Leasing

Rentals payable under operating leases are dealt with in the Profit and Loss Account as incurred over the period of the rental agreement.

## **T.A. Dolan (Pharmacy) Limited**

# **NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 31 March 2025

### **Stocks**

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

### **Trade and other debtors**

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

### **Borrowing costs**

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

### **Provisions**

Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

### **Trade and other creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

### **Employee benefits**

Short term benefits, including holiday pay, are recognised as an expense in the period in which employees have become entitled to the benefits as a result of service rendered to the company.

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

### **Taxation and deferred taxation**

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

### **Ordinary share capital**

The ordinary share capital of the company is presented as equity.

## T.A. Dolan (Pharmacy) Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

### 3. Critical Accounting Judgements and Estimates

The directors consider the accounting estimates and assumptions below to be its critical accounting judgements and estimates:

#### Recoverability of debtors

Estimates are made in respect of the recoverable value of trade and other debtors. When assessing the level of provisions required, factors including trade experience, historical experience and the age profile of debtors are considered.

#### Impairment of tangible assets

The carrying value of tangible assets is assessed for impairment based on the identification of impairment indicators - where events or changes in circumstances indicate that the carrying amount may not be recoverable. This is done by comparing the asset's carrying value to the higher of its value in use and net realisable value (fair value less costs to sell). Any shortfall is recorded as an impairment charge. The assets value in use is based on estimates of future cash flows discounted appropriately. Net realisable value is estimated using a valuation process.

#### Valuation of land

The directors have included an estimated site value for freehold land which was not separately identifiable on acquisition.

|    |   |               |               |
|----|---|---------------|---------------|
| 4. | <b>Operating profit</b>                           | <b>2025</b>   | <b>2024</b>   |
|    |   | €             | €             |
|    | <b>Operating profit is stated after charging:</b> |               |               |
|    | Depreciation of tangible assets                   | <u>77,999</u> | <u>79,379</u> |
| 5. | <b>Interest payable and similar expenses</b>      | <b>2025</b>   | <b>2024</b>   |
|    |   | €             | €             |
|    | Interest  | <u>15,820</u> | <u>20,781</u> |

Bank loans include a number of separate bank loans on which Interest is charged at varying rates from 1.76% to 3.95% per annum. Bank loans are repayable by instalments.

### 6. Employees

The average monthly number of employees, including directors, during the financial year was 13, (2024 - 10).

## T.A. Dolan (Pharmacy) Limited

### NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

#### 7. Tangible assets

|                               | Freehold<br>land and<br>buildings<br>€ | Long<br>leasehold<br>property<br>€ | Fixtures,<br>fittings and<br>equipment<br>€ | Total<br>€       |
|-------------------------------|--|------------------------------------|---|------------------|
| <b>Cost</b>                   |  |                                    |   |                  |
| At 1 April 2024               | 894,922                                | 1,486,163                          | 413,683                                     | 2,794,768        |
| At 31 March 2025              | 894,922                                | 1,486,163                          | 413,683                                     | 2,794,768        |
| <b>Depreciation</b>           |  |                                    |   |                  |
| At 1 April 2024               | 183,120                                | 571,680                            | 340,409                                     | 1,095,209        |
| Charge for the financial year | 14,120                                 | 54,585                             | 9,294                                       | 77,999           |
| At 31 March 2025              | 197,240                                | 626,265                            | 349,703                                     | 1,173,208        |
| <b>Net book value</b>         |  |                                    |   |                  |
| At 31 March 2025              | <u>697,682</u>                         | <u>859,898</u>                     | <u>63,980</u>                               | <u>1,621,560</u> |
| At 31 March 2024              | <u>711,802</u>                         | <u>914,483</u>                     | <u>73,274</u>                               | <u>1,699,559</u> |

Freehold land of €188,922 (2024: €188,922) which is not depreciated is included in freehold land and buildings.

| 8. Stocks        | 2025<br>€      | 2024<br>€      |
|------------------|----------------|----------------|
| Goods for resale | <u>150,258</u> | <u>137,452</u> |

There are no material differences between the replacement cost of stock and the balance sheet amounts.

| 9. Debtors                            | 2025<br>€      | 2024<br>€      |
|---------------------------------------|----------------|----------------|
| Trade debtors                         | 258,862        | 254,872        |
| Directors' current accounts (Note 16) | 40,000         | 37,597         |
| Taxation                              | 18,880         | 6,204          |
| Prepayments                           | -              | 4,026          |
|                                       | <u>317,742</u> | <u>302,699</u> |

All debtors are due within one year

| 10. Creditors                              | 2025<br>€      | 2024<br>€      |
|--|----------------|----------------|
| <b>Amounts falling due within one year</b> |                |                |
| Amounts owed to credit institutions        | 181,747        | 158,551        |
| Trade creditors                            | 234,027        | 235,552        |
| Taxation                                   | 123,879        | 67,276         |
| Other creditors                            | 12,450         | 4,807          |
| Accruals                                   | 10,474         | 11,174         |
|  | <u>562,577</u> | <u>477,360</u> |

## T.A. Dolan (Pharmacy) Limited

### NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

|     |  |                           |                  |
|-----|--|---------------------------|------------------|
| 11. | <b>Creditors</b>   | 2025                      | 2024             |
|     | Amounts falling due after more than one year   | €                         | €                |
|     | Amounts owed to credit institutions  | <u>254,792</u>            | <u>399,874</u>   |
|     | <b>Amounts owed to credit institutions</b>   |                           |                  |
|     | Repayable in one year or less, or on demand  | 181,747                   | 158,551          |
|     | Repayable between one and two years  | 86,671                    | 135,734          |
|     | Repayable between two and five years   | 93,337                    | 180,491          |
|     | Repayable in five years or more  | 74,784                    | 83,649           |
|     |  | <u>436,539</u>            | <u>558,425</u>   |
| 12. | <b>Details of creditors</b>  | 2025                      | 2024             |
|     | Debts falling due for repayment after the end of five years  | €                         | €                |
|     | <b>Creditors repayable by instalments:</b>   |                           |                  |
|     | Amounts owed to credit institutions  | <u>74,784</u>             | <u>83,649</u>    |
|     | <b>Security given in respect of creditors</b>  |                           |                  |
|     | The amounts owed to credit institutions are secured by way of a floating debenture over the leasehold property at Medical Hall, Moate, Co. Westmeath, a fixed charge over the freehold property at Main Street, Moate, Co. Westmeath and a first legal charge over the land at Moranstown, Ballynacargy, Co. Westmeath. Guarantees are also held by the bank for the following amounts; €1,348,000; €140,000; €100,000; €763,000 & €400,000. |                           |                  |
| 13. | <b>Provisions for liabilities</b>  |                           |                  |
|     | The amounts provided for deferred taxation are analysed below:   |                           |                  |
|     |  | <b>Capital allowances</b> | <b>Total</b>     |
|     |  |                           | <b>Total</b>     |
|     |  | 2025                      | 2024             |
|     |  | €                         | €                |
|     | At financial year start  | 4,907                     | 4,348            |
|     | Charged to profit and loss   | 548                       | 559              |
|     | At financial year end  | <u>5,455</u>              | <u>4,907</u>     |
| 14. | <b>Profit and loss account</b>   |                           |                  |
|     |  | 2025                      | 2024             |
|     |  | €                         | €                |
|     | At 1 April 2024  | 1,277,786                 | 1,238,431        |
|     | Profit for the financial year  | 5,158                     | 39,355           |
|     | At 31 March 2025   | <u>1,282,944</u>          | <u>1,277,786</u> |

**T.A. Dolan (Pharmacy) Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 31 March 2025

**15. Financial commitments**

Total future minimum lease payments under non-cancellable operating leases are as follows:

|                    | Land and Buildings |                |
|--------------------|--------------------|----------------|
|                    | 2025               | 2024           |
| Due:               | €                  | €              |
| In over five years | <u>280,488</u>     | <u>329,268</u> |

**16. Directors' remuneration and transactions**

|                                | 2025           | 2024           |
|--------------------------------|----------------|----------------|
|                                | €              | €              |
| <b>Directors' remuneration</b> |                |                |
| Remuneration                   | 137,880        | 137,880        |
| Pension contributions          | 4,895          | 4,895          |
|                                | <u>142,775</u> | <u>142,775</u> |

As permitted by the Companies Act 2014 the following interest free loans were made to the directors:

|              | Balance at    | Advances     | Repayments     | Amounts   | Balance at    |
|--------------|---------------|--------------|----------------|-----------|---------------|
|              | 31/03/25      |              |                | waived in | 31/03/24      |
|              | €             | €            | €              | year      | €             |
|              |               |              |                | €         |               |
| Robert Dolan | <u>40,000</u> | <u>4,106</u> | <u>(1,703)</u> | -         | <u>37,597</u> |

Value of the above arrangements with directors expressed as a percentage of the company's net assets;

|              | 01/04/24     | 31/03/25     | 01/04/23     | 31/03/24     |
|--------------|--------------|--------------|--------------|--------------|
| Robert Dolan | <u>2.94%</u> | <u>3.12%</u> | <u>3.05%</u> | <u>2.94%</u> |

**17. Controlling interest**

Robert Dolan controls the company on the basis that he owns 100% of the issued ordinary share capital of the company.

**18. Post-Balance Sheet Events**

There have been no significant events affecting the company since the financial year-end.

**19. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 23 December 2025.